Locations:
Search IconSearch
October 4, 2018/Cancer

PSA Testing: A Brief Note on Current Thinking

The short answer from the front line of prostate cancer screening

650×450-Doctor-and-Male-Patient

Q: What is your current thinking around the PSA test for prostate cancer detection?

A: The death rate from prostate cancer among U.S. men has fallen more than 30 percent since the introduction of the PSA test in 1990, as the result of earlier diagnosis and improved treatments.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

But what also resulted in the years after its introduction was overdetection and overtreatment of a substantial number of low-grade cancers that posed no immediate risk to patients. In 2012, the U.S. Preventative Services Task Force published a controversial recommendation against regular preventive PSA screening, based on potential harms caused by overtreatment of low-risk cancers, such as the risk of sepsis from biopsy and treatment-related side effects, including changes in urinary, bowel and sexual function.

Since then, several large, long-term trials (including randomized trials in the U.S. and Europe and a recent cohort study with 16-year follow-up) have established that there is indeed benefit to population-level PSA screening. At the same time, there has been an effort within the urology community to better identify and manage patients with non-lethal cancers who are appropriate candidates for active surveillance regimens. A randomized trial and two large prospective cohort studies support the long-term safety of this strategy in select patients, and recently commercialized gene expression profiling tools have great potential to further improve risk stratification.

This year, the USPSTF updated its PSA testing recommendations, stating that men between the ages of 55 and 69 should make individual decisions on PSA screening with input from an informed provider. Men over 70, however, are still not recommended for PSA screening.

Prostate cancer screening reduces mortality and the burden of metastatic disease, and the paradigm continues to evolve. There is reason for optimism about continued improvement to diagnostic accuracy and a reduction in overdetection, with promising research emerging on second-generation PSA tests, multiparametric MRI and germline genomics testing.

Advertisement

Men who are at risk for prostate cancer because of their age, family history, race or newly identified factors (such as germline genetics) deserve an informed discussion with their provider on the benefits and risks of screening.

— Urologist Eric Klein, MD

Advertisement

Related Articles

Surgeon
June 30, 2025/Cancer/News & Insight
Potential for Deintensification of Surgical Interventions in Low-Risk Breast Cancer

Reconsidering axillary lymph node dissection as well as depth of surgical margins

Dendritic cell
June 26, 2025/Cancer/News & Insight
Avelumab Induces Natural Killer Cell Activation and Dendritic Cell Crosstalk

Researchers uncover profound differences in the mechanism of action between different PD-L1 checkpoint inhibitors

World map
June 19, 2025/Cancer/News & Insight
Breaking Barriers to Cancer Care: Cleveland Clinic’s Global Approach

A multi-pronged strategy for tackling cancer access problems

CAR T-cell therapy illustration
June 12, 2025/Cancer/News & Insight
First-Ever U.S. Trial of CAR T-Cell Therapy for Relapsed/Refractory AL Amyloidosis

Early results show patients experiencing deep and complete response

Genomic profiling
June 10, 2025/Cancer
Cleveland Clinic’s Hemato-Oncology Team Spearheads the Development of Guidelines for Genomic Profiling of MDS to Inform Allo-HCT

Inclusion of genomic profiling and risk factors recommended for treatment planning

scan showing cholangiocarcinoma
June 5, 2025/Cancer/News & Insight
Exploring Novel Therapeutic Avenues in Advanced Cholangiocarcinoma: Lessons from the EA2187 Trial

Collaborative research effort underscores the urgent need for effective second-line therapies in this rare, aggressive cancer

Anticoagulant sign
June 4, 2025/Cancer/News & Insight
Direct-Acting Oral Anticoagulants Safe for Patients with Brain Metastasis

Largest study to date comparing direct-acting oral anticoagulants to low-molecular-weight heparin

Ad